TrialPath
Recruiting

Feasibility, Accuracy, and Reproducibility of Virtual Reality Visual Field Testing in Patients With Glaucoma

NCT07063537 · Nova Scotia Health Authority
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Evaluation of the Accuracy and Reproducibility of Visual Field Testing Using a Virtual Reality Head-Mounted Device for Patients With Early, Moderate, and Advanced Glaucoma
About this study
The proposed study aims to evaluate the global and pointwise accuracy and reproducibility of a virtual reality (VR) based visual field testing system on a Pico VR platform in direct comparison to the current standard Zeiss Humphrey Field Analyzer (HFA) in glaucoma patients with various levels of decreased visual field sensitivities. Specifically, we aim to evaluate (1) if both devices produce similar global and pointwise threshold values; (2) the reproducibility of threshold values across the entire tested visual field; (3) whether the stage of glaucoma impacts the accuracy and reproducibility between the two devices; (4) whether scotomas exhibit similar threshold sensitives and reproducibility between the two devices; and (5) differences in reported reliability indices between the two devices. Each participant will perform visual field testing for both eyes using both the VR visual field system and HFA (order randomized). Five separate sessions (both tests for each patient; both eyes) will be conducted, at least 24 hours apart. Patients will also be asked to fill out a questionnaire to qualitatively evaluate their perception of each visual field test.
Eligibility criteria
Inclusion Criteria: * \>18 years of age * diagnosis of primary open-angle glaucoma * ability to perform visual field testing * capacity to provide informed consent to research protocol Exclusion Criteria: * diagnosis of secondary glaucoma or non-glaucomatous optic neuropathy * previous intraocular surgery (excluding cataract surgery and minimally invasive glaucoma surgery) * significant media opacity * pregnancy * seizure disorder * cardiac pacemaker/other implantable device * severe vertigo/balance disorder
Study design
Enrollment target: 60 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2024-12-14
Estimated completion: 2025-10
Last updated: 2025-07-14
Interventions
Device: Virtual Reality Visual Field (VR-VF)
Primary outcomes
  • • Visual field point-wise threshold values (Measured during each visual field test on visits 1 through 5 (throughout study completion, average 2 months))
  • • Global indices of visual field loss (Measured during each visual field test on visits 1 through 5 (throughout study completion, average 2 months))
  • • Reliability Indices (Measured during each visual field test on visits 1 through 5 (throughout study completion, average 2 months))
Sponsor
Nova Scotia Health Authority · other
Contacts & investigators
ContactReann Post, BSc · contact · reann.post@dal.ca · 19029560601
ContactLynn Murphy · contact · lynn@eadietech.com · 19024072380
InvestigatorBrennan Eadie, MD, PhD, FRCSC · principal_investigator, Nova Scotia Health
All locations (1)
Eadie Technologies IncRecruiting
Halifax, Nova Scotia, Canada
Feasibility, Accuracy, and Reproducibility of Virtual Reality Visual Field Testing in Patients With Glaucoma · TrialPath